• BV6 (SKU B4653): Optimizing IAP Antagonist Assays in Cancer

  2026-05-11

  This scenario-driven guide explores the practical challenges faced by researchers performing apoptosis, proliferation, and cytotoxicity assays, highlighting how BV6 (SKU B4653) addresses reproducibility, sensitivity, and workflow efficiency. Integrating data-backed evidence and real-world lab contexts, we demonstrate why BV6—sourced from APExBIO—stands out as a robust IAP antagonist for translational oncology and endometriosis models.

• WEHI-539: Precision BCL-XL Inhibition for CSC Apoptosis Insi

  2026-05-10

  Explore how WEHI-539, a potent BCL-XL inhibitor, uniquely advances apoptosis research by dissecting cancer stem cell survival mechanisms. This article offers a distinct, assay-focused perspective for researchers seeking deeper insights into BCL-XL-mediated pathways.

• Ibrexafungerp vs. Fluconazole-Resistant Candida auris: Effic

  2026-05-09

  This study rigorously evaluates ibrexafungerp’s in vitro and in vivo efficacy against fluconazole-resistant Candida auris using delayed-treatment murine models. The findings highlight ibrexafungerp’s robust antifungal activity even when fluconazole, a standard ergosterol biosynthesis inhibitor, is ineffective—informing future approaches to multidrug-resistant fungal infections.

• Colistin–Gamithromycin Synergy in Neutropenic Murine Pneumon

  2026-05-08

  Li et al. demonstrated that combining colistin with gamithromycin substantially enhances antimicrobial efficacy against multidrug-resistant Pasteurella multocida in a neutropenic murine lung model. This synergistic effect reduced required antibiotic concentrations and offers key insights for optimizing therapies against Gram-negative respiratory infections.

• Optimizing Native Protein Gel Electrophoresis with Kit K4142

  2026-05-08

  This article addresses real laboratory challenges in native protein gel electrophoresis and demonstrates how the Basic Protein Native PAGE Gel Preparation and Electrophoresis Kit (PI ≤ 7.0) (SKU K4142) delivers reproducible, activity-preserving results for acidic proteins. Scenario-driven Q&A blocks guide researchers through protocol optimization, data interpretation, and reliable vendor selection, with evidence-based recommendations and workflow insights.

• Sabutoclax: Pan-Bcl-2 Inhibitor for Advanced Cancer Assays

  2026-05-07

  Sabutoclax, a potent pan-Bcl-2 inhibitor, empowers researchers to dissect apoptosis pathways across diverse cancer models with high selectivity and permeability. This article translates cutting-edge systems biology insights and reference-driven metrics into optimized workflows, troubleshooting strategies, and protocol enhancements.

• Distinct Apoptotic Pathways in Bovine Cells by Candida kruse

  2026-05-07

  This study demonstrates that the yeast and hypha phases of Candida krusei induce apoptosis in bovine mammary epithelial cells (BMECs) via different molecular signaling pathways. These findings refine our understanding of fungal mastitis pathogenesis and suggest new avenues for targeted apoptosis inhibition in veterinary and translational research.

• Harnessing BV6: IAP Antagonist Workflows for Apoptosis Resea

  2026-05-06

  BV6, a selective IAP antagonist, transforms apoptosis and radiosensitization research with robust, reproducible protocols. This guide delivers actionable workflows, troubleshooting strategies, and experimental insights for maximizing BV6's impact in cancer and endometriosis models.

• Q-VD-OPh: Unraveling Apoptosis Reversal and Cell Survival Pa

  2026-05-06

  Explore how Q-VD-OPh, a potent pan-caspase inhibitor, is driving breakthroughs in apoptosis research by illuminating the mechanisms of cell survival after caspase activation. This article uniquely connects recent kinome screening insights with advanced protocol guidance.

• Novobiocin: Aminocoumarin Antibiotic for Advanced Bench Assa

  2026-05-05

  Novobiocin stands out as a dual-action aminocoumarin antibiotic, targeting both bacterial DNA gyrase and Hsp90 for robust antibacterial, antiparasitic, and antiviral research. This article delivers actionable workflows, troubleshooting guidance, and direct translations from the latest reference study to empower advanced bench applications.

• Sabutoclax as a Pan-Bcl-2 Inhibitor: Quantitative Assay Stra

  2026-05-05

  Explore how Sabutoclax, a potent pan-Bcl-2 inhibitor, unlocks advanced quantitative assays for apoptosis induction in cancer cells. This article reveals assay design strategies, uniquely integrating the latest in vitro evaluation frameworks to guide reproducible, translational research.

• Generation of iPSC Lines from MDD and BD Patients: A Dyad Mo

  2026-05-04

  This study reports the derivation and thorough characterization of two induced pluripotent stem cell (iPSC) lines from a genetically related mother–son pair affected by major depressive disorder and bipolar disorder, respectively. These lines provide a controlled genetic platform for dissecting disease-specific and shared mechanisms in psychiatric research, enabling more precise exploration of molecular pathophysiology and therapeutic development.

• A-1331852 in Precision Apoptosis Research: Selectivity, Assa

  2026-05-04

  Explore how the potent BCL-XL inhibitor A-1331852 is redefining apoptosis assay precision and translational cancer research. This article uniquely analyzes selectivity, mechanistic insights, and critical protocol parameters for advanced experimental design.

• Oral CXCR4 Antagonist Mavorixafor: Phase 3 Results in WHIM S

  2026-05-03

  Badolato et al. present a pivotal phase 3 clinical trial evaluating mavorixafor, an oral CXCR4 antagonist, in patients with WHIM syndrome. The study demonstrates significant improvements in neutrophil and lymphocyte counts and a notable reduction in infection rates, marking a substantial advancement in targeted therapy for this rare immunodeficiency.

• ONX-0914 (PR-957): Applied Immunoproteasome Inhibition in Au

  2026-05-02

  ONX-0914 (PR-957) is a highly selective immunoproteasome inhibitor transforming workflows in autoimmune and inflammatory disease research. This article distills evidence-based protocols, cross-validates with recent studies, and delivers troubleshooting tactics to unlock reproducible cytokine modulation using APExBIO’s trusted compound.

16675 records 3/1112 page Previous Next 12345 下5页 Last page